

clinical
dosing
95% CI
genotype-guided
trials
randomized
weeks
warfarin
buprenorphine
percentage
oat

intervention
clinical
injury
treatment
control
trajectories
disability
recovery
placebo
support
randomized

95% CI
handover
group
major
years
mechanical
issues
ratio
mortality
morning
valve

studies
patients
care
bacteremia
surgery
review
aureus
antibiotic
veterans
cancer
ventilation

patients
95% CI
melanoma
outcomes
fracture
measures
cell
setting
new
death
nursing

devices
interventions
adherence
95% CI
patients
medication
adverse
children
improved
data
decrease

patients
survival
mortality
associated
95% CI
mh-aged
risk
factors
study
skin
hazard

participants
children
measures
symptoms
disorder
depression
age
behavior
treatment
severity
baseline

health
participants
care
information
outcomes
mh-health
children
95% CI
secondary
quality
measures

cancer
95% CI
risk
years
screening
ezetimibe
prostate
areas
survival
disorder
age

—3.479

—2.915

—2.351

—1.787

—1.223

patients
weight
obesity
loss
guidelines
smoking
clinicians
overweight
engagement
lifestyle
urinary

genetic
functional
brain
disease
connectivity
gene
schizophrenia
expression
mutations
imaging
importance

care
patients
hospital
pain
discharge
visits
faculty
medical
minority
department
emergency

patients
disease
levels
mg-aged
imaging
cognitive
diabetes
burden
healthy
surgery
older

95% CI
risk
patients
older
years
headache
kidney
acute
treatment
children
statin

patients
outcomes
complications
mortality
mh-aged
cohort
surgical
risk
hospital
age
postoperative

group
patients
95% CI
placebo
treatment
randomized
therapy
clinicaltrials
mh-aged
interventions
trial
difference

gastric
patients
treatment
studies
bypass
genotype
index
diabetes
loss
weight
therapy

patients
diagnostic
cases
days
95% CI
glucose
accuracy
physicians
mh-aged
median
confidence